Clinical Podcasts Archive


Information contained in the following UpToDate Talk podcasts was current at the time of initial release. However, this content is not maintained or updated. For current clinical recommendations, please always consult UpToDate Online. Please note that we are no longer producing new clinical podcasts.

UpToDate faculty discuss important changes to the practice of medicine based in our clinical podcasts. Our contributors are recognized physician leaders in their fields and offer their expertise regarding each update and its impact on clinical practice.

Support for UpToDate Talk is provided by UpToDate, Wolters Kluwer. UpToDate is entirely funded by the subscriptions of its users and does not accept advertising or funding unrelated to subscriptions. The opinions in such podcasts are entirely those of the discussants, and these discussants are authors and editors for UpToDate. View the UpToDate conflict of interest policy.

This is the complete archive for the UpToDate Clinical Talk Podcasts.

Screening for diabetes mellitus

Date Released: May 18 2016

This episode features Dr. David Nathan discussing screening adults for type 2 diabetes and increased risk for diabetes, and new recommendations for such screening as part of cardiovascular risk assessment. Dr. Nancy Sokol hosts.

Tables referenced in audio:

Diagnostic criteria: Diabetes and high risk for diabetes

Screening recommendations for diabetes and pre-diabetes in asymptomatic adults

Dr. NathanDr. David Nathan is a Professor of Medicine at Harvard Medical School and Director of the Diabetes Center at Massachusetts General Hospital in Boston.
  1. Siu AL, U S Preventive Services Task Force. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2015; 163:861.


David M Nathan, MD Nothing to disclose


Hodgkin lymphoma survivors; medical management of pediatric appendicitis; PPIs and dementia risk

Date Released: Apr 21 2016

In this episode, Dr. Andrea Ng discusses second cancers in Hodgkin lymphoma survivors (starts at 01:13); Dr. David Mooney discusses nonoperative management for children with uncomplicated appendicitis (starts at 10:22); and Dr. Steven DeKosky discusses proton pump inhibitors and risk of dementia in older adults (starts at 21:07). Dr. Nancy Sokol hosts.

Dr. NgDr. Andrea Ng is a Professor of Radiation Oncology at Harvard Medical School and serves on the Steering Committee of the International Radiation Oncology Lymphoma Group.
Dr. MooneyDr. David Mooney is an Associate Professor of Surgery at Harvard Medical School, Pediatric Surgeon and Director of the Trauma Program at Children’s Hospital in Boston.
Dr. DeKoskyDr. Steven DeKosky is a Professor of Neurology at the University of Florida College of Medicine and Interim Executive Director of the McKnight Brain Institute.

Segment on Hodgkin lymphoma survivors (Dr. Ng):

  1. Schaapveld M, Aleman BM, van Eggermond AM, et al. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med 2015; 373:2499.

Segment on medical management of pediatric appendicitis (Dr. Mooney):

  1. Minneci PC, Mahida JB, Lodwick DL, et al. Effectiveness of Patient Choice in Nonoperative vs Surgical Management of Pediatric Uncomplicated Acute Appendicitis. JAMA Surg 2015; :1.

Segment on PPIs and dementia risk (Dr. DeKosky):

  1. Gomm W, von Holt K, Thomé F, et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol 2016; 73:410.
  2. Close

Andrea Ng, MD, MPH Nothing to disclose

David Mooney, MD Nothing to disclose

Steven DeKosky, MD Consultant: Novartis Pharmaceuticals; Roche Pharmaceuticals; Acumen Pharmaceuticals; Biogen; Cognition Therapeutics [Healthcare consultations].


DAPT Score for coronary stents; Bronchoscopic interventions for severe emphysema; Beers criteria

Date Released: Mar 16 2016

In this episode, Dr. Christopher Cannon discusses decisions about stopping dual antiplatelet therapy in patients with intracoronary stents (starts at 01:21); Dr. Tom Gildea discusses novel bronchoscopic interventions on the horizon for patients with severe emphysema (starts at 11:45); and Dr. Paula Rochon discusses the updated Beers criteria to guide appropriate use of pharmacotherapy in older adults (starts at 22:52). Dr. Nancy Sokol hosts.

Dr. NathanDr. Christopher Cannon is a Professor of Medicine at Harvard Medical School, a senior physician at Brigham and Women’s Hospital, and Executive Director of Cardiometabolic Trials at the Harvard Clinical Research Institute.
Dr. BartlettDr. Tom Gildea is a pulmonologist and head of the Section of Bronchoscopy at the Respiratory Institute at the Cleveland Clinic.
Dr. FreemanDr. Paula Rochon is a Professor in the Department of Medicine and Institute of Health Policy Management and Evaluation at the University of Toronto, Vice President of Research at the Women’s College Hospital, and Retired Teachers of Ontario Chair in Geriatric Medicine at the University of Toronto.

Segment on DAPT Score for coronary stents (Dr. Cannon):


Segment on Bronchoscopic interventions for severe emphysema (Dr. Gildea):

  1. Klooster K, Ten Hacken NH, Hartman JE, et al. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J Med 2015; 373:2325.
  2. Deslée G, Mal H, Dutau H, et al. Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial. JAMA 2016; 315:175.

Segment on Beers criteria (Dr. Rochon):

  1. American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc 2015.


Christopher P Cannon, MD Grant/Research Support: Accumetrics (Platelets and ACS [Verify Now platelet test]); Arisaph (Lipids); AstraZeneca (ACS, lipids, and GI [Ticagrelor, Rosuvastatin, PPI]); Boehringer-Ingelheim (AF [Dabigatran]); CSL Behring (Lipids); Essentialis (Lipids); GlaxoSmithKline (Lipids and DM); Janssen (AF and DM [Rivaroxaban and Cangliflozen); Merck (Lipids [Ezetimibe]); Regeneron (Lipids); Sanofi (Lipids and ACS [clopidogrel]); Takeda (DM [Pioglitazone]). Consultant/Advisory Boards: Bristol-Myers Squibb (AF [Apixaban]); Lipimedix (Lipids); Pfizer (AF, DM, and Lipids [Apixaban, Etrugliflozin, Atorvastatin]); Kowa (lipids).

Thomas R Gildea, MD, MS Grant/Research/Clinical Trial Support: PneumRx [Emphysema (Coil trial)]; Spiration [Emphysema (Valve trial)]; Aeris [Emphysema (Biologic LVR)]; Emphasys [Emphysema (Local investigator in clinical trial)].

Paula A Rochon, MD, MPH, FRCPC Nothing to disclose.


SPRINT Trial; Recurrent Wheezing in Children; HTN in Pregnancy and Risk of Congenital Heart Defects

Date Released: Feb 17 2016

This episode features Dr. George Bakris, discussing the SPRINT Trial (starts at 01:01); Dr. Robert Wood, discussing azithromycin in the treatment of recurrent wheezing in young children (starts at 16:20), and Dr. Charles Lockwood discussing hypertension and its treatment during pregnancy in relation to congenital heart defects (starts at 25:33). Dr. Anna Feldweg hosts.

Dr. NathanDr. George Bakris is Professor of Medicine at the University of Chicago Medicine where he is director of the American Society of Hypertension Comprehensive Hypertension Center.
Dr. BartlettDr. Robert Wood is a Professor of Pediatrics at Johns Hopkins University School of Medicine, Chief of the Division of Allergy and Immunology, and Professor of International Health at the Johns Hopkins Bloomberg School of Public Health.
Dr. FreemanDr. Charles Lockwood is a Professor of Obstetrics and Gynecology and Dean of the Morsani College of Medicine at the University of South Florida.

Segment on SPRINT Trial (Dr. Bakris):

  1. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373:2103.

Segment on Recurrent Wheezing in Children (Dr. Wood):

  1. Bacharier LB, Guilbert TW, Mauger DT, et al. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. JAMA 2015; 314:2034.

Segment on HTN in Pregnancy and Risk of Congenital Heart Defects (Dr. Lockwood):

  1. Ramakrishnan A, Lee LJ, Mitchell LE, Agopian AJ. Maternal Hypertension During Pregnancy and the Risk of Congenital Heart Defects in Offspring: A Systematic Review and Meta-analysis. Pediatr Cardiol 2015; 36:1442.


George L Bakris, MD Grant/Research/Clinical Trial Support: Bayer, Boehringer-Ingelheim, Relypsa, Vascular Dynamics, Medtronic [Diabetic neuropathy, diabetes, hypertension (Empagliflozin, patriromer)]. Consultant/Advisory Boards: AstraZeneca, Arbor Pharmaceuticals, Bayer, Boehringer-Ingelheim, Relypsa, Vascular Dynamics, Medtronic [Diabetic neuropathy, diabetes, hypertension (Empagliflozin, patriromer)].

Robert A Wood, MD Grant/Research/Clinical Trial Support: DBV [Food allergy]. Consultant/Advisory Boards: Sanofi [Food allergy (Epinephrine)]; Stallergenes [Allergic rhinitis (Sweet vernal/orchard/perennial rye/timothy/Kentucky blue grass mixed pollen allergen extract - sublingual route)].

Charles J Lockwood, MD, MHCM Consultant/Advisory Boards: Celula [Aneuploidy screening (Prenatal and cancer DNA screening tests in development)].